Abingdon HealthABDXF 49 Cash Ratio is 1.06 as of Dec. 2025, which is 22% above its 10-year median of 0.87. GuruFocus rates ABDXF with a GF Score™ of 49/100 and a GF Value™ of $0.21 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 209 Medical Diagnostics & Research companies, Abingdon Health ranks better than 52.63% on this metric.
Abingdon Health has a Cash Ratio of 1.06. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Abingdon Health's Cash Ratio or its related term are showing as below:
ABDXF'
s Cash Ratio Range Over the Past 10 Years
Min: 0.45 Med: 0.87 Max: 2.11
Current: 1.06
During the past 8 years, Abingdon Health's highest Cash Ratio was 2.11. The lowest was 0.45. And the median was 0.87.
ABDXF's Cash Ratio is ranked better than 52.63% of 209
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.97
vs ABDXF: 1.06
Abingdon Health (OTCPK:ABDXF) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Abingdon Health Cash Ratio Related Terms
Abingdon Health Cash Ratio Historical Data
* Premium members only.
The historical data trend for Abingdon Health's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Abingdon Health's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Abingdon Health Cash Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Abingdon Health's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Abingdon Health's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Abingdon Health (ABDXF) has a Cash Ratio of 1.06 as of Dec. 2025. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Abingdon Health and its competitors. This is 22% above median its historical median of 0.87. Over the past decade, Abingdon Health's Cash Ratio has ranged from 0.45 to 2.11. According to the industry distribution chart, Abingdon Health ranks #99 out of 209 companies in the Medical Diagnostics & Research industry, placing it in the top 47.4%.
Is Abingdon Health's Cash Ratio too high?
Abingdon Health's current Cash Ratio of 1.06 is 22% above median its 10-year median of 0.87. Over the past 10 years, this metric has ranged from a low of 0.45 to a high of 2.11. The Medical Diagnostics & Research industry median Cash Ratio is 0.97. Abingdon Health's value of 1.06 is 9.3% above this industry median. Based on the distribution chart, Abingdon Health ranks #99 out of 209 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Abingdon Health has a GF Score™ of 49/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Abingdon Health's Cash Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Abingdon Health ranks #99 out of 209 companies for Cash Ratio. This puts Abingdon Health in the upper half of its industry. The industry median Cash Ratio is 0.97. Abingdon Health's value of 1.06 is 9.3% above this benchmark. Historically, Abingdon Health's own Cash Ratio has ranged from 0.45 to 2.11 over the past decade. While the company's 10-year median is 0.87 vs. the industry median of 0.97, Abingdon Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Medical Diagnostics & Research company?
The median Cash Ratio among Medical Diagnostics & Research companies is 0.97, based on 209 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Abingdon Health's current Cash Ratio of 1.06 is 9.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Abingdon Health and its competitors. For the Medical Diagnostics & Research industry, the median Cash Ratio is 0.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Abingdon Health's current Cash Ratio is 1.06, which is 22% above median its own 10-year median of 0.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abingdon Health stock overvalued right now?
Based on GuruFocus' analysis, Abingdon Health (ABDXF) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.21, compared to a current price of $0.15 — trading 26.4% below its estimated fair value. The current Cash Ratio is 1.06, which is 22% above median its 10-year median of 0.87 and 9.3% above the Medical Diagnostics & Research industry median of 0.97. Abingdon Health's overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Abingdon Health (ABDXF), the current Cash Ratio is 1.06 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Abingdon Health (ABDXF) Overvalued in 2026?
Based on GuruFocus' analysis, Abingdon Health stock appears to be undervalued.
The current stock price of $0.15 is trading 26.4% below its estimated GF Value™ of $0.21.
GuruFocus considers Abingdon Health to be Modestly Undervalued.
Key valuation signals for ABDXF:
Cash Ratio: 1.06 (22% above median its 10-year median of 0.87)
GF Value™: $0.21 vs. price of $0.15 (26.4% below fair value)
Industry Position: 9.3% above the Medical Diagnostics & Research median (#99 of 209)
No single metric tells the full story. See the ABDXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Abingdon Health PLC develops, manufactures, and distributes diagnostic devices and provides regulatory consultancy to diagnostics businesses. It offers integrated lateral flow CRO/CDMO services covering feasibility, manufacturing, packaging, kitting, documentation, and commercial support. Segments include Contract Development (milestone-based third-party work, revenue over time by completion), Contract Manufacturing (development/manufacturing via daily consultancy, revenue at customer control point), Product Sales (AbC-19TM, Pocket Diagnostic, PCRD tests, research antibodies, carriage; point in time), and Regulatory Services (IVD/medical device compliance, revenue over time), with key revenue from Regulatory Services. It operates in the UK, USA/Canada, Europe, and rest of world.
49GF Score
Get the complete analysis for ABDXF
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ABDXF has been successfully added to your 
